Skip to main content
Equibles
IGC logo

IGC · IGC Pharma, Inc.

Track IGC — free

Use IGC with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about IGC

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.30 +0.00 (+1.33%) At close · Aug 25
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company assesses and determines its ability to continue as a going concern in accordance with the provisions of ASC Subtopic 205-40, "Presentation of Financial Statements—Going Concern", which requires the Company to evaluate whether there are conditions or events that raise substantial doubt about its ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$31.84M
Shares
103.38M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.30 Open$0.30 Day$0.30–0.31 52W close$0.24–0.47 Avg vol 30d698K Short int768K · 0.7% float · 1.0d Short vol31% DataJan 2020–Aug 2026 Filing10-Q · Aug 14

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 14, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.5 · calm Equity put/call 0.57
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +4%
above
Price vs 50-day avg +12%
above
RSI (14) 64
neutral
MACD trend Positive
52-week position 28%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +17%
trailing
6-month return +5%
trailing
YTD return +9%
this year
Relative strength −7%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Accumulating
+6% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.74% of float · ▲ +41.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
36 holders — near 3-yr high, broad support
Squeeze score 45
elevated · 0–100
Fundamentals
Strong
Revenue growth −6%
Y/Y
Gross margin 49%
contracting
EPS growth +59%
Y/Y
Free cash flow $-4.9M
Balance sheet $499.0K
net cash
Quant / Vol
risk profile
Very High
Volatility 55%
annualized · 1-yr
Max drawdown −49%
past year
ATR 4.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+4% Bullish
Price vs 50-day avg
+12% Bullish
RSI (14)
64 Neutral
MACD trend
Positive Bullish
52-week position
28% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Accumulating
+6% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.74% of float · ▲ +41.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
36 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $0 Now $0 · 28% Range high $0
vs 200-day avg +4% vs 50-day avg +12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IGC
IGC Pharma, Inc.
this stock
$31.84M +8.8% +39.5% — 0.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.79B +21.9% +46.2% 31.9 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.30B +8.0% +20.8% 20.5 2.3%
ARGX
Argenx SE
 $63.81B +21.2% — — 1.9%
CSLLY
Csl Ltd
 $60.07B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
36
% held
5.0%
Net QoQ
+1.6M sh
Top holder
GEODE CAPITAL MANAGEMENT,…
Held Float
View
Held by Funds
Fund positions
5
View
Short & Settlement
Short Interest Rising
Shares short
767.6K
Days to cover
1.0d
Change
+225.9K sh
View
Short Volume
Short vol %
31%
As of
Aug 25, 2026
Short Total
View
Fails to Deliver
FTD shares
113
Value
$28
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
73.2%
Week of
Jul 20, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$1.3M
Net income (FY)
$-7.1M
EPS diluted
$-0.09
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 14, 2026
This year
10
View
Proposed Sales
Value
$78.2K
Shares
200.0K
Filed
Aug 9, 2024
View

Performance

5D 20D 120D MTD YTD
IGC +7.1% +17.2% +5.0% +21.8% +8.8%
SPY -0.2% +3.4% +11.8% +2.5% +12.3%
vs SPY +7.3% +13.8% -6.8% +19.3% -3.5%
Key facts CIK 1326205 CUSIP 45408X308 13F (30d) 31 filings 31 filers Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)